Suggestions
Nick Plugis
Senior Principal at Flagship Pioneering
Nick Plugis is a Senior Principal at Flagship Pioneering, a prominent biotech venture creation and investment firm.2 He works on a venture-creation team to found and grow companies based on innovative biological concepts and emerging technologies.2
Professional Background
Nick joined Flagship Pioneering after completing the company's Fellows Program.3 His work at Flagship has led to the creation of several groundbreaking biotech companies, including:
- Ring Therapeutics: Focused on revolutionizing gene therapy using a commensal virome platform1
- Cellarity: Designing medicines targeting cell behavior rather than single molecular targets1
- Laronde: Pioneering endless RNA (eRNA™), a new class of programmable medicines1
Previously, Nick served as the Chief Innovation Officer at Cellarity, where he created and led the company's Drug Design Studio. This initiative combined systems biology, single-cell technologies, and machine learning to develop new cell-centric chemical design capabilities.1
Education and Achievements
Nick holds a Ph.D. in Chemistry from Stanford University, where he worked with Chaitan Khosla as part of the ChEM-H innovation hub.1 His research focused on building and using chemical biology tools to investigate the molecular pathophysiology of celiac disease.1 He also completed the Stanford Graduate School of Business's Ignite Program.1
For his undergraduate studies, Nick earned a B.A. in Chemistry and Economics from Middlebury College.1
Nick's innovative work has resulted in multiple patents and publications.1 In 2021, he was recognized in Business Insider's list of 12 serial entrepreneurs building the next generation of biotech startups.1
Current Role and Impact
As a Senior Principal at Flagship Pioneering, Nick continues to play a crucial role in the creation and development of cutting-edge biotech companies. His expertise spans various fields, including synthetic biology, chemical biology, and the application of AI in drug discovery.14
Highlights
Congrats to the Abiologics team on today's unveiling!
Abiologics is surpassing the limits of nature to create Synteins™, a new class of supranatural and programmable biologics that aims to redefine what therapeutics can achieve for patients across a range of disease areas.
It was a pleasure working alongside Noubar Afeyan, Avak Kahvejian, Mike Hamill, Jaclyn Dunphy, Kala Subramanian, Alicia Kaestli, PhD, Peter Rapp, Luke Dowman, and Parashar Thapa Ph.D. in the early days of the company. I'll be cheering on the team as they strive to bring this new category of medicine to patients.
If you're interested in learning more, check out the open roles: https://lnkd.in/e-4zty9G
#biotechnology #drugdiscovery #startup #FlagshipFounded
I’m happy to share that I’m starting a new position as Senior Principal at Flagship Pioneering!
